China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei and currently employs 2,867 full-time employees. The company went IPO on 2004-12-02. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The firm operates its business in mainland China and Hong Kong markets.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
3,344
3,778
4,516
3,950
3,223
2,655
Revenue Growth (YoY)
-20%
-16%
14%
23%
21%
-2%
Cost of Revenue
890
946
1,122
1,012
813
667
Gross Profit
2,453
2,831
3,394
2,938
2,410
1,987
Selling, General & Admin
1,700
1,895
2,313
2,107
1,763
1,458
Research & Development
106
100
110
117
112
99
Operating Expenses
1,638
1,817
2,260
2,111
1,773
1,472
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
1,058
1,145
1,240
917
720
395
Income Tax Expense
230
305
270
194
163
99
Net Income
828
840
969
722
556
295
Net Income Growth
-25%
-13%
34%
30%
88%
-41%
Shares Outstanding (Diluted)
755.4
755.4
755.4
755.4
755.14
756.74
Shares Change (YoY)
0%
0%
0%
0%
0%
-3%
EPS (Diluted)
1.09
1.11
1.28
0.95
0.73
0.38
EPS Growth
-25%
-13%
34%
30%
89%
-39%
Free Cash Flow
799
823
788
980
609
572
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
73.35%
74.93%
75.15%
74.37%
74.77%
74.83%
Operating Margin
24.34%
26.81%
25.08%
20.91%
19.73%
19.39%
Profit Margin
24.76%
22.23%
21.45%
18.27%
17.25%
11.11%
Free Cash Flow Margin
23.89%
21.78%
17.44%
24.81%
18.89%
21.54%
EBITDA
--
1,081
1,310
1,011
818
723
EBITDA Margin
--
28.61%
29%
25.59%
25.38%
27.23%
D&A For EBITDA
--
68
177
185
182
208
EBIT
814
1,013
1,133
826
636
515
EBIT Margin
24.34%
26.81%
25.08%
20.91%
19.73%
19.39%
Effective Tax Rate
21.73%
26.63%
21.77%
21.15%
22.63%
25.06%
Follow-Up Questions
What are China Shineway Pharmaceutical Group Ltd's key financial statements?
According to the latest financial statement (Form-10K), China Shineway Pharmaceutical Group Ltd has a total asset of $10,041, Net profit of $840
What are the key financial ratios for CSWYF?
China Shineway Pharmaceutical Group Ltd's Current ratio is 3.9, has a Net margin is 22.23, sales per share of $5.
How is China Shineway Pharmaceutical Group Ltd's revenue broken down by segment or geography?
China Shineway Pharmaceutical Group Ltd largest revenue segment is Injections, at a revenue of 1,374,777,459 in the most earnings release.For geography, China including Hong Kong is the primary market for China Shineway Pharmaceutical Group Ltd, at a revenue of 4,096,244,475.
Is China Shineway Pharmaceutical Group Ltd profitable?
yes, according to the latest financial statements, China Shineway Pharmaceutical Group Ltd has a net profit of $840
Does China Shineway Pharmaceutical Group Ltd have any liabilities?
yes, China Shineway Pharmaceutical Group Ltd has liability of 2,574
How many outstanding shares for China Shineway Pharmaceutical Group Ltd?
China Shineway Pharmaceutical Group Ltd has a total outstanding shares of 827